|
|
|
| home > ebr > Autumn 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
|
Prepared to Launch
Mike Rea at IDEA Pharma considers the importance of product lifecycle decisions and explains how assessing commercial and regulatory risk, in addition to considerations of investment and time-to-market, can lead to a strong competitive advantage.
.jpg)
|
|
|
|
App Potential
As the internet promotes customer satisfaction by encouraging feedback via online publications, the importance of maintaining a web presence is growing. Kelly Sladek at SCORR Marketing outlines the inevitable evolution of online promotions. |
|
|
|
Digital Exchange
A recent survey demonstrates an increasing dependence on electronic communication media within the biotech sector. Linda Bowers at IntraLinks evaluates the implementation of web-based document exchange solutions. |
|
|
|
|
Trimming the Fat
Lean Six Sigma has been proven to be an effective and helpful tool for contract laboratories providing biopharmaceutical analysis. Melanie Dippel at Charles River Biopharmaceutical Services GmbH looks at benefi cial collaborations with an outsourcing partner. |
|
|
|
|
The Biotechisation of Pharma
With the noticeable rise of ‘biotechisation’ in pharma companies in recent years, Flavia Botschen and Markus Thunecke at Catenion look at how this will affect all related branches of the densely interwoven biopharmaceutical industry.
|
|
|
|
|
|
Protein Production
Igor A Kaltashov at the University of Massachusetts-Amherst assesses the advantages and challenges of mass spectrometry-based methods used for characterising protein as well as its broader impact on the production process. |
|
|
|
|
|
Flow Cytometry Outsourcing
Carla G Hill and Thomas W McCloskey at ICON Central Laboratories report on how the use of flow cytometry for clinical trial testing is set to increase, as accurate evaluation of cell-based biomarker assays becomes a necessity in the assessment of biologic drug candidates. |
|
|
|
|
|
Cause and Effect
Biomarkers are integral to improved diagnostics and novel therapeutics. Ioannis Amarantos, Thomas Laufer and Thomas Brefort at febit biomed GmbH study their four primary categories of application and discuss research case studies of miRNA development.
|
|
|
|
|
Regulatory Challenges
The Survey Says
Alan Trounson and Elona Baum at the California Institute for Regenerative Medicine (CIRM) run through their research on current perspectives regarding regulatory uncertainty when facing challenges for commercialisation in the fi eld of regenerative medicine. |
|
|
|
|
Single-Use Technology
At Your Disposal
Nicole O’Brien at Gallus BioPharmaceuticals discovers that the road to a fully disposable biomanufacturing process – from bench to commercial production – is just on the horizon, and offers an insight into how it is transforming biotherapeutics. |
|
|
|
|
Peptide Synthesis
Building Bonds
In-depth knowledge of peptide production methods to optimise yield and purity is critical to faster and more cost-effective commercialisation of peptidebased therapies, elaborates Gary Hu at the American Peptide Company. |
|
|
|
|
|
Drawn to Scale
Successful manufacturing of biopharmaceuticals relies on good process design, scale up and control strategies. Graham McCreath and Mahesh Shivhare at Fujifilm Diosynth Biotechnologies demonstrate the possibilities that small scale fermentation can offer.
|
|
|
|
|
Setting Your Sites
While there are numerous challenges for the effective contact research management of most clinical trials, oncology studies pose even further complications. Erin Anderson and Daryl Ann Fallon of Premier Research Group Limited focus on the goals and objectives the biotechnology sector face today.
|
|
|
|
Peptide Potential
Citing recent research into the potential of a synthetic peptide known as ‘p28’, Tapas K Das Gupta, David R Volk and Craig W Beattie at CDG Therapeutics, Inc relate how new findings on this peptide could alter future cancer therapies. |
|
|
|
|
Express Delivery
siRNAs have proved their capacity to perform in a wide range of applications, from human diseases to plant pathogen resistance. Kathleen Hefferon at the University of Toronto explains how their development has been adapted within the medicinal and agricultural fi elds. |
|
|
|
|
The Future’s Orange
Annemiek Verkamman at Life Sciences Health looks at the social, technological and sector trends within the Dutch life sciences industry as these companies compete to be global players.
 |
|
|
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE
Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.
More info >> |
|
 |
White Papers |
 |
|
Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices
Phillips-Medisize
An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed
clinical trials can all benefit from these novel, next-generation technologies.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
